Effect of spironolactone and minoxidil solution in treatment of androgenic alopecia
Phase 2
- Conditions
- Androgenic alopecia.Androgenic alopecia
- Registration Number
- IRCT20181005041243N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Aged 18-60
Clinical diagnosis of androgenic alopecia with a dermatologist
Have not received any drug for alopecia in the past 12 months
Exclusion Criteria
Pregnancy or breastfeeding during the intervention
history of internal diseases, including endocrine diseases causing alopecia
alteration in diet and lifestyle during the study
polycystic ovary syndrome
The disease caused by another reason than androgenic alopecia
Consuming any systemic or topical drugs which caused hair loss or hair regrowth
Have a history of hair transplantation
History of skin diseases which cause hair loss like cutaneous cancers, infection, psoriasis
photosensitivity
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hair regrrowth score. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Hair regrowth score based on the observations of two dermatologists assessing the before and after photographs.
- Secondary Outcome Measures
Name Time Method Patients' satisfaction with androgenic alopecia recovery. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Visual Analogue Scale.;Hair regrowth score based on Fotofinder device. Timepoint: At the beginning of the study (before the start of the intervention) and 6 months after the start of trial. Method of measurement: Hair density (hairs/cm2) and Hair diameter (hairs/cm2).